# Development of a Next-Generation Immunoprevention Platform Against HIV-1

> **NIH NIH N43** · NEOVAXSYN, INC. · 2024 · $300,000

## Abstract

Development of Next-Generation Devices and Materials-Based Platforms for the Administration of HIV-1 Broadly Neutralizing Antibodies: NIAID and its partners are building on the success of the Antibody Mediated Prevention (AMP) trials by engineering next-generation broadly neutralizing antibody (bNAb) candidates to enhance potency, increase tissue levels, extend half-life, and contend with the ever-evolving global diversity of HIV-1. Developing bNAb cocktails presents additional challenges: complex pharmacokinetics, larger injection volumes, multi-product formulations, and complicated manufacturing. The goal of this program is to support small businesses in the development of devices and/or materials for administration of HIV-1 bNAb(s) and bNAb derivatives (e.g., bispecific antibodies), resulting in increased protection from infection. The goal of this contract is to develop a novel polymer-based InterPenetrating Network Film (IPNF) to maintain high titer bnAbs in the female vaginal tract.

## Key facts

- **NIH application ID:** 11171823
- **Project number:** 75N93024C00050-0-9999-1
- **Recipient organization:** NEOVAXSYN, INC.
- **Principal Investigator:** Santanu Raychaudhuri
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $300,000
- **Award type:** —
- **Project period:** 2024-08-01 → 2025-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11171823

## Citation

> US National Institutes of Health, RePORTER application 11171823, Development of a Next-Generation Immunoprevention Platform Against HIV-1 (75N93024C00050-0-9999-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/11171823. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*